Assessment of the relative potency of emtricitabine and lamivudine [2] (multiple letters)

Journal of Acquired Immune Deficiency Syndromes

Volumn 34, Issue 2, 2003, Pages 243-246

  Schinazi, Raymond F ^a   Hazen, Richard ^b   Lanier, E Randall ^b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; DIDANOSINE; EMTRICITABINE; LAMIVUDINE; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; CELL TYPE; CLINICAL TRIAL; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; LETTER; MACROPHAGE; MONONUCLEAR CELL; NONHUMAN; PRIORITY JOURNAL; VIRUS ISOLATION;

ANTI-HIV AGENTS; CELLS, CULTURED; DEOXYCYTIDINE; HIV-1; HUMANS; LAMIVUDINE;

EID: 0141889167     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200310010-00017     Document Type: Letter

References (0)